<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00559377</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00257</org_study_id>
    <secondary_id>NCI-2009-00257</secondary_id>
    <secondary_id>UW IRB# 6143</secondary_id>
    <secondary_id>7958</secondary_id>
    <secondary_id>N01CM37008</secondary_id>
    <nct_id>NCT00559377</nct_id>
  </id_info>
  <brief_title>FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer</brief_title>
  <official_title>A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well PET scans using fluoromisonidazole F 18 and
      fludeoxyglucose F 18 work in finding oxygen in tumor cells of patients undergoing treatment
      for newly diagnosed stage 1B, stage II, stage II, or stage IV cervical cancer. Diagnostic
      procedures using positron emission tomography (PET scan), fluoromisonidazole F 18, and
      fludeoxyglucose F 18 to find oxygen in tumor cells may help doctors predict how patients will
      respond to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Test the extent to which fluoromisonidazole F 18 ([^18F] FMISO) uptake predicts survival
      of patients undergoing therapy for newly diagnosed stage IB-IVB cervical cancer.

      SECONDARY OBJECTIVES:

      I. Test [^18F] FMISO tumor uptake as an independent predictor of response to therapy and that
      it provides additional predictive power over fludeoxyglucose F 18 ([^18F] FDG).

      II. Test [^18F] FMISO tumor uptake as a predictor of response in a subgroup of patients
      receiving radiotherapy.

      III. Test the relationship between [^18F] FMISO uptake in the primary tumor and the volume of
      the primary tumor estimated by CT scan.

      IV. Test the reproducibility of [^18F] FMISO uptake in tumors by imaging the same patients on
      sequential days in a test-retest protocol.

      V. Compare [^18F] FMISO PET or PET/CT scan with [^18F] FDG PET or PET/CT scan to test whether
      [^18F] FMISO is an independent predictor of treatment outcome.

      OUTLINE:

      Patients receive fluoromisonidazole F 18 ([^18F] FMISO) IV over 1 minute followed by PET
      scanning. Patients undergo a second [^18F] FMISO PET scan 4-8 weeks later. Patients who have
      not had a prior fludeoxyglucose F 18 ([^18F] FDG) PET scan as part of their routine clinical
      management undergo [^18F] FDG PET scanning at baseline. A subset of 10 patients undergo two
      [^18F] FMISO PET scans within a 48-hour period to evaluate the variability (test-retest) of
      this imaging measurement.

      Patients response to therapy is followed periodically until time to disease progression or
      for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>For up to 2 years</time_frame>
    <description>Evaluate the value of pre-treatment FMISO results (T:B and HV) for all patients to predict the survival outcome variables.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free Survival (DFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Evaluate the value of pre-treatment FMISO results (T:B and HV) for all patients to predict the disease free survival outcome variables.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Hypoxia-related IHC Biomarkers and Regional FMISO Uptake in Tumor</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The value of the biomarker by IHC analyses relates primarily to validating the information content of FMISO images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship Between Ki67 and Regional FMISO Uptake in Tumor</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The value of the biomarker Ki67 analyses relates primarily to validating the information content of FMISO images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to XRT Using RECIST</measure>
    <time_frame>time to disease progression or 2 years following first FMISO scan</time_frame>
    <description>Response for the XRT is evaluated by the radiation oncologists as per standard clinical protocols</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Cervical Adenocarcinoma</condition>
  <condition>Cervical Squamous Cell Carcinoma</condition>
  <condition>Stage IB Cervical Cancer</condition>
  <condition>Stage IIA Cervical Cancer</condition>
  <condition>Stage IIB Cervical Cancer</condition>
  <condition>Stage III Cervical Cancer</condition>
  <condition>Stage IVA Cervical Cancer</condition>
  <condition>Stage IVB Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic FMISO AND FDG PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ^18F FMISO IV over 1 minute followed by PET scanning. Patients undergo a second ^18F FMISO PET scan 4-8 weeks later. Patients who have not had a prior ^18F FDG PET scan as part of their routine clinical management undergo ^18F FDG PET scanning at baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-fluoromisonidazole</intervention_name>
    <description>Undergo ^18F FMISO PET scan</description>
    <arm_group_label>Diagnostic FMISO AND FDG PET</arm_group_label>
    <other_name>18F-FMISO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fluorodeoxyglucose F 18</intervention_name>
    <description>Undergo ^18F FDG PET scan</description>
    <arm_group_label>Diagnostic FMISO AND FDG PET</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Undergo ^18F-FMISO and ^18F FDG PET scan</description>
    <arm_group_label>Diagnostic FMISO AND FDG PET</arm_group_label>
    <other_name>FDG-PET</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>tissue oxygen measurement</intervention_name>
    <description>Undergo ^18 F FMISO PET and ^18F FDG PET</description>
    <arm_group_label>Diagnostic FMISO AND FDG PET</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed squamous cell or adenocarcinoma of the uterine cervix

          -  Clinical stage IB-IVB by FIGO criteria

               -  Size of the primary tumor ≥ 2 cm as assessed by CT scan

          -  Measurable disease

          -  Scheduled to undergo radiotherapy, chemotherapy, or combined multimodality management

          -  No prior cervical cancer diagnosis

          -  No known brain metastases

          -  ECOG performance status (PS) 0-2 (Karnofsky PS 60-100%)

          -  Life expectancy &gt; 12 months

          -  Not pregnant

          -  No nursing for 24 hours after fluoromisonidazole F 18 ([^18F] FMISO) PET scanning

          -  Negative pregnancy test

          -  Weight ≤ 400 lbs

          -  Sufficiently healthy to undergo cancer treatment

          -  Willing to undergo PET scanning with urinary bladder catheterization

          -  Leukocytes ≥ 3,000/mm³

          -  Absolute neutrophil count ≥ 1,500/mm³

          -  Platelet count ≥ 100,000/mm³

          -  Total bilirubin normal

          -  AST/ALT ≤ 2.5 times normal

          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min

          -  No serious medical co-morbidities that would preclude definitive local therapy

          -  No history of allergic reactions attributed to compounds of similar chemical or
             biologic composition to [^18F] FMISO

          -  No concurrent uncontrolled illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Psychiatric illness/social situations that would limit compliance with study
                  requirements.

          -  No prior surgery or radiotherapy for cervical cancer

          -  Other concurrent investigational agents allowed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Rajendran</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2007</study_first_submitted>
  <study_first_submitted_qc>November 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2007</study_first_posted>
  <results_first_submitted>October 29, 2014</results_first_submitted>
  <results_first_submitted_qc>June 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 26, 2015</results_first_posted>
  <last_update_submitted>December 28, 2016</last_update_submitted>
  <last_update_submitted_qc>December 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
    <mesh_term>Misonidazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic (^18F FMISO PET and ^18F FDG PET)</title>
          <description>Patients receive ^18F FMISO IV followed by PET scanning. Patients undergo a second ^18F FMISO PET scan 4-8 weeks later. Patients who have not had a prior ^18F FDG PET scan as part of their routine clinical management undergo ^18F FDG PET scanning at baseline.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>Patients receive ^18F FMISO IV followed by PET scanning. Patients undergo a second ^18F FMISO PET scan 4-8 weeks later.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>Evaluate the value of pre-treatment FMISO results (T:B and HV) for all patients to predict the survival outcome variables.</description>
        <time_frame>For up to 2 years</time_frame>
        <population>1 patient has been lost to follow up for survival measures.</population>
        <group_list>
          <group group_id="O1">
            <title>2 Year Overall Survival</title>
            <description>Patients who have not been declared deceased for 2 years after their last FMISO scan.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Evaluate the value of pre-treatment FMISO results (T:B and HV) for all patients to predict the survival outcome variables.</description>
          <population>1 patient has been lost to follow up for survival measures.</population>
          <units>participants still alive after 2 years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This outcome is for comparing FMISO Hypoxic Volume to overall survival</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.42</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.27</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This outcome is for comparing FMISO T:Bmax to overall survival</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.87</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.05</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival (DFS)</title>
        <description>Evaluate the value of pre-treatment FMISO results (T:B and HV) for all patients to predict the disease free survival outcome variables.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Of the 13 patients analyzed for disease-free survival, 10 remained disease-free throughout the 2 year follow up. For 3 patients, we could determine overall survival, but could not confirm whether or not they were disease-free.</population>
        <group_list>
          <group group_id="O1">
            <title>Disease-Free Survival</title>
            <description>Patients who have remained disease-free throughout the 2 year follow up</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (DFS)</title>
          <description>Evaluate the value of pre-treatment FMISO results (T:B and HV) for all patients to predict the disease free survival outcome variables.</description>
          <population>Of the 13 patients analyzed for disease-free survival, 10 remained disease-free throughout the 2 year follow up. For 3 patients, we could determine overall survival, but could not confirm whether or not they were disease-free.</population>
          <units>participants disease-free after 2 years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This outcome is for comparison of FMISO Hypoxic Volume to disease-free survival</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.58</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.18</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>This outcome is for comarison of FMISO T:Bmax to progression-free survival</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.98</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>.99</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Hypoxia-related IHC Biomarkers and Regional FMISO Uptake in Tumor</title>
        <description>The value of the biomarker by IHC analyses relates primarily to validating the information content of FMISO images.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>11 tissue samples with Hif1, VEGF, p53 and EGFR IHC values were compared to FMISO uptake.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With IHC Measures</title>
            <description>Patients who had tissue used to evaluate immunohistochemistry measures correlated to FMISO uptake where IHC scores were calculated by standard Allred values.</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Hypoxia-related IHC Biomarkers and Regional FMISO Uptake in Tumor</title>
          <description>The value of the biomarker by IHC analyses relates primarily to validating the information content of FMISO images.</description>
          <population>11 tissue samples with Hif1, VEGF, p53 and EGFR IHC values were compared to FMISO uptake.</population>
          <units>units on a scale 0=low, 8=high</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hif1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p53</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="4" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>EGFR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The correlation between IHC values and FMISO uptake were analyzed using Spearman correlation where p values less than 0.05 were considered significant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Spearman Correlation</method>
            <param_type>Spearman Correlation</param_type>
            <param_value>.004</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relationship Between Ki67 and Regional FMISO Uptake in Tumor</title>
        <description>The value of the biomarker Ki67 analyses relates primarily to validating the information content of FMISO images.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>11 tissue samples with Ki67 values were compared to FMISO uptake.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With IHC Measures</title>
            <description>Patients who had tissue used to evaluate immunohistochemistry measures correlated to FMISO uptake where IHC scores were calculated by standard Allred values.</description>
          </group>
        </group_list>
        <measure>
          <title>Relationship Between Ki67 and Regional FMISO Uptake in Tumor</title>
          <description>The value of the biomarker Ki67 analyses relates primarily to validating the information content of FMISO images.</description>
          <population>11 tissue samples with Ki67 values were compared to FMISO uptake.</population>
          <units>percentage of staining</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" spread="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to XRT Using RECIST</title>
        <description>Response for the XRT is evaluated by the radiation oncologists as per standard clinical protocols</description>
        <time_frame>time to disease progression or 2 years following first FMISO scan</time_frame>
        <population>PET/CT acquisition was obtained using non-diagnostic low dose CT attenuation scans at the time of PET/CT imaging that limited our ability to accurately measure tumor dimensions and due to lack of complete data, we were not able to fulfill this aim.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Who Had Response Determined by Clinical RECIST</title>
          </group>
        </group_list>
        <measure>
          <title>Response to XRT Using RECIST</title>
          <description>Response for the XRT is evaluated by the radiation oncologists as per standard clinical protocols</description>
          <population>PET/CT acquisition was obtained using non-diagnostic low dose CT attenuation scans at the time of PET/CT imaging that limited our ability to accurately measure tumor dimensions and due to lack of complete data, we were not able to fulfill this aim.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>As a PET imaging study, AEs are assessed at 3 hours post injection (end of the scan) and up to 10 hours following the scan</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic (^18F FMISO PET and ^18F FDG PET)</title>
          <description>Patients receive ^18F FMISO IV followed by PET scanning. Patients undergo a second ^18F FMISO PET scan 4-8 weeks later. Patients who have not had a prior ^18F FDG PET scan as part of their routine clinical management undergo ^18F FDG PET scanning at baseline.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small number of subjects enrolled and events limit meaningful statistical analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joseph G Rajendran</name_or_title>
      <organization>UWMC Dept of Radiology</organization>
      <phone>206-221-4421</phone>
      <email>rajan@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

